New Delhi, March 24: The Drugs Controller of India has intensified regulatory oversight against the unauthorized sale and promotion of weight loss medications, specifically GLP-1 based drugs, to ensure ethical pharmaceutical practices within the supply chain.
Concerns have emerged regarding the availability of various generic variants of GLP-1-based weight loss drugs through retail pharmacies, online platforms, wholesalers, and wellness clinics, particularly in light of their recent entry into the Indian market. The misuse of these medications without proper medical supervision can lead to serious side effects and associated health risks.
In response to this situation, the Drugs Controller, in collaboration with state regulators, has initiated several targeted actions to prevent potential malpractice in the pharmaceutical supply chain and to curb unauthorized sales and usage.
On March 10, 2026, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting “surrogate advertisements” (indirect promotions) and any form of misleading advertising that could mislead consumers or promote “off-label use” (utilization of the drug for unapproved purposes).
Enforcement activities have significantly ramped up in recent weeks, with audits and inspections conducted on 49 entities, including online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics. These inspections were carried out across various regions of the country, primarily aimed at identifying unauthorized sales, improper prescriptions, and violations related to misleading marketing. Additionally, notices have been sent to entities found in violation of regulations.
The regulator emphasizes that patient safety is paramount. The misuse of weight loss drugs without medical supervision can lead to severe health complications. Citizens are advised to use such medications only under the guidance of qualified medical professionals.
In India, these drugs have been approved with the stipulation that they can only be prescribed by endocrinologists and internal medicine specialists, and in specific cases, by cardiologists. Regulatory oversight will be further intensified in the coming weeks, with strict actions against non-compliance, including license revocation, fines, and legal proceedings under applicable laws.